QWINT-3 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin degludec for 78 weeks in adults with type 2 diabetes currently treated with basal insulin.

In this randomized controlled trial, insulin alfa efsitora (efsitora) demonstrated noninferiority to degludec in reducing ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

The results of the ONWARDS 2 trial of insulin icodec showed that it was as effective as daily dosing with Novo Nordisk's Tresiba (insulin degludec) once per day at controlling blood glucose, as ...

Ryzodeg ® 70/30 contains two types of insulin: Basal insulin called insulin degludec - this has a long blood sugar level lowering effect. Rapid-acting insulin called insulin aspart - this lowers ...

People using a hybrid closed-loop system are more likely to have better HbA1c levels than those using open-loop therapies, a ...

including long-acting insulin degludec, rapid-acting insulin aspart, and premix insulin preparations including the combination of insulin degludec and aspart. To improve the convenience of our ...

Ryzodeg ® 70/30 contains two types of insulin: Basal insulin called insulin degludec - this has a long blood sugar lowering effect. Rapid acting insulin called insulin aspart - this lowers your ...

Eli Lilly has released detailed results from the Phase III QWINT-2 and QWINT-5 trial showing that its once weekly insulin efsitora (efsitora alfa) demonstrated a similar reduction in HbA1C levels ...